Gastroesophageal junction carcinoma (GEJ) is a difficult-to-treat malignancy that constitutes a large minority of all gastric cancers. One of the key difficulties in treating the disease is the ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

EFS and pCR are the KEYNOTE-522 trial’s dual primary endpoints, and overall survival is a key secondary endpoint. In the current analysis, Keytruda’s EFS benefit remained strong, with the drug ...

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...